We further explored the therapeutic potential of ANC@RNP/crEGFR‐PLK1 in an orthotopic patient‐derived xenograft (PDX) model constructed from patient‐derived glioma stem cells (GSCs).[21] The use of GSCs‐based models better recapitulates the natural process of carcinogenesis, tumor heterogeneity, accelerated tumor growth, and the development of resistance to therapy.[27] As a result, GSCs have emerged as a new therapeutic target in patients with glioblastoma. This evidence concerns the gene PLK1 and central nervous system cancer.